METHODS:
A prospective, longitudinal, controlled interventional analysis was conducted in seven patients with CD in clinical remission and 10 HC to investigate the effect of orally administrated vitamin D on the intestinal bacterial composition using 16S ribosomal RNA gene amplicon sequencing. Clinical parameters were assessed.
RESULTS:
In contrast to HC, microbial communities of CD patients changed significantly during early vitamin D administration. However, a further increase in vitamin D level was associated with a reversal of this effect and additionally with a decrease in the bacterial richness in the CD microbiome. Specific species with a high abundancy were found during vitamin D administration in CD, but not in HC; the abundancy of Alistipes, Barnesiella, unclassified Porphyromonadaceae (both Actinobacteria), Roseburia, Anaerotruncus, Subdoligranulum and an unclassified Ruminococaceae (all Firmicutes) increased significantly after 1-week vitamin D administration in CD.
INTRODUCTION

Inflammatory bowel diseases (IBD) consist of
Crohn's disease (CD) and ulcerative colitis (UC) which are chronic inflammatory diseases of the alimentary tract. 1 While the pathogenesis is still not completely understood, an important part of the disease is known to be inappropriate activation of the mucosal immune system caused by intestinal microbiota in patients with a genetical risk profile. [1] [2] [3] [4] Mutations in the nucleotide-binding oligomerization domain-containing protein 2 (NOD2) gene, encoding for the NOD2 receptor, are major risk factors for the development of CD. [5] [6] [7] [8] In addition, environmental factors, such as vitamin D deficiency, seem to play a role in the pathogenesis of IBD as well. 8, 9 Vitamin D is commonly known as an important regulator of calcium and phosphate metabolism and is therefore essential for bone health. 10, 11 However, there is increasing evidence that vitamin D also plays an important role as a regulator of the innate and adaptive immune system. [11] [12] [13] In a murine colitis model, the application of 1,25-dihydroxyvitamin D 3 (1, 25 [OH] 2 D 3 ) was associated with reduced mucosal injury.
14 Vitamin D deficiency is highly prevalent in IBD patients. 15, 16 Interestingly, stimulation with vitamin D increased the expression of the NOD2 receptor in primary monocytic and epithelial cells, linking the innate immune system with vitamin D. 17 Vitamin D was shown to have an effect on the dendritic and monocyte-derived macrophages cell function. [19] [20] [21] From a clinical point of view, the administration of tumor necrosis factor (TNF)-alpha inhibitor is associated with higher vitamin D levels in IBD. 18 On the other hand, in CD patients where infliximab was initiated, lower vitamin D levels were associated with a higher rate of clinical remission at week 14.
22
Even now, it is still not clear whether vitamin D administration has a beneficial effect on the disease course in IBD. In a prospective study, infliximab treatment had a positive effect on bone metabolism. 23 Along the same line in different studies in CD patients, an inverse association between vitamin D levels and intestinal inflammation was found. 24, 25 In several interventional studies, vitamin D administration appeared to have beneficial effects on the clinical disease activity and Creactive protein (CRP) values in IBD patients. [26] [27] [28] [29] However, whether vitamin D also has an influence on the intestinal bacterial composition is still not known. In murine models, vitamin D and the vitamin D receptor (VDR) are important regulators of intestinal bacterial composition. [30] [31] [32] In a recent genome-wide association study (GWAS), mutations in the VDR gene were associated with different intestinal microbial profiles. 33 To address the hypothesis, whether administration of vitamin D has an effect on the intestinal microbial communities in CD, we performed a controlled prospective and longitudinal analysis in CD patients in clinical remission and healthy controls (HC).
MATERIAL AND METHODS
Study design
The study was approved by the Institutional Review Board of the University Medical Center Rostock (A 2016-0109). The study was registered in the German Clinical Trials Register (Registration number DRKS00013485). Written informed consent was obtained from each participant prior to their enrollment.
Seven patients with ileocolonic CD (Montreal classification 34 : L3) and vitamin D deficiency (25[OH] D <75 nmol/L) were recruited from the Outpatient Clinic of Rostock University Medical Center (Rostock, Germany). The patients were in clinical remission and did not have a change of their CD-specific therapy during the previous 6 months before they were enrolled in this study. HC with vitamin D deficiency and no history of IBD were recruited from the Rostock Medical School. In both groups, oral vitamin D administration was given with cholecalciferol (MIBE GmbH Arzneimittel, Brehna, Germany) 20 000 IU daily from day 1 until day 3, then every other day for a total of 4 weeks. In this study, a target vitamin D level was set to be between 100 and 150 nmol/L. Serum 25-hydroxyvitamin D (25[OH]D) levels were measured weekly (before administration = week 0). In both groups, 300 000 IU vitamin D were administered per patient over the course of the study. In CD patients, calprotectin levels were measured at week 0 and week 4. Fresh stool samples were collected weekly (weeks 0, 1, 2, 3 and 4) for analysis of the intestinal bacterial microbiota. The disease activity in CD patients was assessed using the Crohn's disease activity index (CDAI); 35 other clinical parameters, including the localization of the disease, medical therapy, duration of the disease, were recorded. Clinical characteristics of all the participants are shown in Table 1 .
DNA extraction
DNA was isolated from whole blood with the QIAamp DNA Blood Mini Kit (Qiagen, Hilden, Germany) according to the instructions of the manufacturer.
NOD2 genotyping
Regarding the NOD2 genotyping we focused on the three major mutations of the NOD2 gene (SNP Table S1 were employed. Additionally, the PCR products were subjected to Sanger sequencing (Seqlab, Göttingen, Germany). The resulting data were analyzed using with the Chromas 2.6 (Technelysium Pty. Ltd., Brisbance, Australia).
Preparation of 16S rRNA gene sequencing libraries, sequencing run and data analysis
The isolated DNA was amplified with the bacterial 16S ribosomal RNA (rRNA) gene primers Bakt_341F (CCTACGGGNGGCWGCAG) and Bakt_805R (GACTACHVGGGTATCTAATCC). 36 The amplicon PCR, the index PCR, a quantity and a quality control and the sequencing of the individual libraries as a pool in one Illumina MiSeq run was performed as described in a previous study. 37 The raw sequences of the study were deposited at the Short Sequence Archive (SRA) under the accession number 'PRJEB21819'. For our data analysis, the resulting sequences were assembled using the program QIIME 1.9.1 38 with the 'joins paired-end Illumina reads' function with default settings to merge forward and reverse sequences with an overlap of at least 30 bp. We discharged sequences without overlap. After converting 'fastq' to 'fasta' using the 'convert_fastaqual_-fastq' function, we used the SILVA NGS pipeline for the resulting sequences, using default settings. 39 This pipeline aligns the reads to a database with the SINA aligner. 40 With this program, problematic reads such as PCR artefacts (including potential chimeras) and non-ribosomal reads are filtered out and consecutively discarded. The reads are then quality filtered using the following settings: reads less than 50 aligned nucleotides and reads with more than 2% of ambiguities, 2% of homopolymers or low alignment quality, defined by a 40 alignment score reported by SINA. After the alignment, the sequences were dereplicated by clustering by a 98% sequence identity to each other using CD-HIT. 41 The longest read in each cluster was Basic Local Alignment Search Tool (BLAST) searched against SILVA SSU Ref 128 to classify the sequences. The resulting classification of the reference sequence of each cluster was mapped to all the members of the cluster as well as their replicates. The sequences which have an average BLAST alignment coverage and alignment identity of less than 93% were considered as unclassified and we defined them as the virtual taxonomical group 'No Relative'.
Statistical analysis
Continuous variables were expressed as mean AE standard deviation or medians and interquartiles, whereas categorical variables were expressed as numbers and percentages. The disease activity, measured by CDAI and the calprotectin value in the CD cohort from week 0 and week 4, was compared using a paired t-test.
Operational taxonomic unit (OTU) counts based on genus level were rarefied to 3500 reads per sample using the single_rarefraction.py script implemented in QIIME. To compare the dominant taxa in the different time points (week 0 until week 4) during vitamin D administration, the occurrence of the 22 most abundant OTUs was visualized in a heatmap using Explicet. 42 This program was also used in a rarefaction-based analysis, here with bootstrapping for richness. We visualized the differences in the bacterial community composition through non-metric Vitamin D administration was associated with a temporal shift of the intestinal microbiota in CD, but not in HC Bacteroidetes and Clostridia were among the most abundant phyla/classes in the bacterial community analysis (Fig. S1 ). This could be observed at all time points (week 0 to week 4) in CD as well as in HC. However, to assess the effect of vitamin D administration on different microbial communities, we visualized changes in the bacterial composition on the bacterial genus levels using NMDS in HC (Fig. 3a) and CD (Fig. 3b) . In the HC group, there was no significant difference between week 0 and week 4 as well as between the different time points of vitamin D administration. In the CD group, we observed a shift of the bacterial composition from week 0 to week 1, which reversed in weeks 2, 3 and 4 (Table S2 ). The shift from week 0 to week 1 was not significant, which might be attributed to the fact that the bacterial composition of two patients at week 0 clustered within the bacterial communities of week 1. The bacterial community at week 1 differed significantly from those at week 2, week 3 and week 4 in all patients during vitamin D administration (week 1 vs week 2, P = 0.007; week 1 vs week 3, P = 0.01; week 1 vs week 4, P = 0.011). In contrast, the bacterial community at week 0 did not differ significantly from those at weeks 2, 3 and 4 (all P > 0.05). The use of TNF-α inhibitor, the disease activity (CDAI) and the presence of a mutation of the NOD2 gene did not have a 
Vitamin D administration was associated with specific abundant bacteria in CD, but not in HC
To further assess if vitamin D has an impact on the abundance of specific strains in CD and HC, we characterized alterations in the bacterial genera using LEfSe. 44 While in CD different specific abundant bacteria before and at different time points during vitamin D administration were found, the analysis of the HC cohort did not detect any abundant strains. The results of the CD group are shown in a heatmap (Fig. 4) . The bacteria were stratified into five groups to differentiate the response to the vitamin D administration (highest abundance at weeks 0 to 4). Before vitamin D administration (week 0) the typical bacteria (significantly more abundant based on LEfSe analysis) were Sutterella (Betaproteobacteria), next to Bifidobacterium (Actinobacteria) and an unclassified lineage of the Lachnospiracea. After 1 week of vitamin D administration (week 1), the typical bacteria shifted toward an Alistipes (Bacteroidetes)-dominated bacterial community. Barnesiella and unclassified Porphyromonadaceae (both Actinobacteria), as well as Roseburia, Anaerotruncus, Subdoligranulum and an unclassified Ruminococaceae (all Firmicutes) were also highly prevalent at this time point. After 2 weeks of vitamin D administration (week 2), the Bacteroidetes became less prominent and Firmicutes, especially Faecalibacterium, Veillonella, and Blautia, Fusicatenibacter and Intestinibacter became the typical part of the bacterial community composition. In the third week of vitamin D administration, Parabacteroides (Bacteroides) were mainly abundant throughout the study but were significantly less abundant in weeks 1-2. Other indicator OTUs were Lachnospira (Firmicutes), Coprobacter (Bacteroides) and Parasutterella (Betaproteobacteria). At week 4, Lactobacillus and Megasphera (both Firmicutes) were significantly enriched. However, both had numerically a relatively low abundance.
Vitamin D administration was associated with a decrease in the bacterial taxa in CD, but not in HC
In previous studies, a reduction of the bacterial diversity was found in CD. 45, 46 To address the question if vitamin D administration also has an effect on the diversity in CD and HC, we analyzed the number of bacterial taxa at the different time points (week 0 until week 4). There was no significant difference between CD and HC in the number of bacterial taxa before vitamin D administration (P > 0.05, Tukey's test). While the number of bacterial taxa in HC did not change significantly (HC: week 0 vs week 4, P > 0.05; Tukey's test), the bacterial taxa in CD decreased significantly during vitamin D administration (CD: week 0 vs week 4, P = 0.001; Tukey's test). Additionally, the number of bacterial taxa was significantly lower in CD compared to HC at weeks 3 and 4 of vitamin D administration (CD vs HC, week 3: P = 0.007, week 4: P = 0.0001; Tukey's test; Fig. 5 ).
DISCUSSION
Dysbiosis is an important feature in the pathogenesis of IBD. [45] [46] [47] [48] Environmental factors such as vitamin D deficiency also seem to play a role in the development and the clinical disease course of IBD. Here we have investigated whether there is an interaction of vitamin D and intestinal microbiota in CD because vitamin D has been shown to have an influence on intestinal inflammation and therefore possibly on microbial communities as well. Vitamin D has been shown to ameliorate intestinal inflammation, but it is not clear whether this is a direct effect on the inflammatory response and the intestinal microbiota is only secondarily altered or whether this is a direct effect on the intestinal microbiota. Therefore, vitamin D was given to HC and CD patients who were in clinical remission to analyze the microbial composition in both groups. Vitamin D administration was associated with a significant shift of the intestinal bacterial communities in CD patients at week 1. While the bacterial composition in HC was not significantly affected by vitamin D administration, we observed temporal changes in the bacterial communities during vitamin D administration in CD patients (Fig. 3) . Vitamin D has therefore a strong effect on the microbial composition in CD, but not in HC, suggesting an important role in the pathogenesis of IBD. The strongest effect was observed at week 1 of vitamin D administration. However, the increase in 25(OH)D levels over three additional weeks caused again a shift in the bacterial community that was more similar to the initial bacterial community at week 0. There may be alternative explanations for the temporal nature of the effect of vitamin D. First, the effect of vitamin D on the bacterial communities is in itself only temporal and the microbiota revert after 2 weeks. Second, there may be an optimal 25 (OH)D level ('vitamin D window') which resembles the vitamin D levels at week 1 (64.6 AE 29.8 nmol/L) and a further increase in vitamin D levels might therefore cause reversal of effect on the bacterial composition.
Another important finding of our study is the change in the bacterial diversity during vitamin D administration (Fig. 5) . Studies found a lower bacterial species diversity in CD patients compared to HC. 49, 50 However, in our study, the number of bacterial taxa was not significantly different between HC and CD before the administration of vitamin D. This might be attributed to the fact that our patients were in stable clinical remission. After 2 weeks of vitamin D administration, the number of bacterial taxa declined in CD patients but did not change in HC. In general, a higher diversity is thought to be associated with beneficial effects for the host. Our results suggest that an increased vitamin D concentration causes a loss of OTUs that are potentially beneficial and supports the 'vitamin D window' hypothesis. However, it can be speculated that week 4 is too early to see a long-term effect of vitamin D administration on the composition of the bacterial communities. Further, prospective studies are needed to test the presence of an optimal vitamin D range in IBD.
The mechanisms of how vitamin D administration leads to a shift of the bacterial communities in CD remains speculative. Several studies have shown a correlation between vitamin D status, the mucosal immune system and the microbiota in IBD. 51, 52 Mutations in VDR are risk factors for the development of IBD 8 and vitamin D can activate the NOD2 pathway. 17 A recent study by Wang et al. showed that variations in VDR had an influence on gut microbiota. 33 For the treatment of IBD, the role of probiotics remains controversial. While in UC probiotics may have a positive effect in specific, well-defined clinical situations, the efficacy of probiotics in CD remains uncertain. 53, 54 In the present analysis we have identified specific bacterial species which show an increased abundance during vitamin D administration. In addition to many other abundant strains, we observed a prominent change in the abundancy of Alistipes and Parabacteroides during vitamin D administration in CD but not in HC. Both species appear to be of special importance in the pathogenesis of IBD. In contrast to the increased abundance of Alistipes, Parabacteroides showed a decreased abundance during vitamin D administration in the first and second week of the study but an increase at week 3 and week 4. In murine dextran sulphate sodium (DSS)-induced colitis, Alistipes finegoldii was protective against colitis. 55 Additionally, in a study using VDR-knockout mice, Alistipes was depleted in cecal stool. 31 Other studies have proposed an important role for Parabacteroides in the pathogenesis of intestinal inflammation and found a decrease in Parabacteroides at inflamed compared to non-inflamed sites of the intestine. 56, 57 Additionally, oral administration of Parabacteroides distasonis led to decreased severity in a murine model of DSS colitis. 58 Interestingly, in our analysis the abundance of Parabacteroides decreased in the first 2 weeks. As a consequence, Alistipes and Parabacteroides might therefore have beneficial effects on the host and vitamin D administration may possibly induce the growth of these species. In addition to these highly abundant species, several other OTUs were found to be significantly increased during vitamin D administration in the first week. These 
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Vitamin D changes microbiome in CD included Roseburia, of which a decrease of Roseburia hominis has been associated with a higher disease activity in UC. 59 Absence of Roseburia before colectomy in UC was associated with a higher risk of pouchitis in UC. 60 Faecalibacterium prausnitzii, which showed high abundance from week 1 to week 3, is a well-known butyrate-producing strain which is thought to have anti-inflammatory properties. [61] [62] [63] A specific microbial community containing Barnesiella, also showing a high abundance at week 1, had beneficial effects on the intestinal microbial composition. 64 We hypothesize from our data that the appearance of several beneficial bacterial strains during vitamin D administration has a protective effect on the disease course in CD. Vitamin D might therefore enhance the probiotic capacity of these strains via an increased abundance. In line with that, vitamin D was required for a positive probiotic effect in a murine colitis model. 65 A combination of probiotics and vitamin D may have a synergistic effect on the disease activity in CD. Further studies will be needed to test this hypothesis.
One aspect of criticism in this study is that the control group was significantly younger than the CD group due to technical reasons, which might also have an effect on the intestinal microbial composition. Although we found a highly significant change of the bacterial communities in CD but not in HC, this effect could also be influenced by the age of the participants in this study. In further studies, agematched control groups might clarify this aspect.
As a conclusion, the administration of vitamin D has a specific impact on the bacterial profile in CD, shown by the shift of the bacterial composition, the different highly abundant and potentially beneficial bacterial strains and the reduced diversity during vitamin D administration. In contrast to CD, in the HC group, no specific effects of vitamin D administration have been detected. This is the first controlled prospective interventional analysis which shows a specific effect of vitamin D administration on the microbial communities in CD, but not in HC. Therefore, vitamin D administration may be an important additional therapeutic intervention in the management of CD.
SUPPORTING INFORMATION
Additional supporting information may be found in the online version of this article at the publisher's website: Figure S1 . Stack bar graphs of the bacterial community composition on phyla/class level at week 0 (w0), week1 (w1), week 2 (w2), week 3 (w3) and week 4 (w4) in Crohn's disease (CD) and healthy controls (HC). Table S1 . Primer and polymerase chain reaction (PCR) conditions for NOD2-genotyping Table S2 . Statistical analysis of the bacterial composition at the different weeks in Crohn's disease (CD) using a Bonferoni corrected PERMANOVA.
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